268 related articles for article (PubMed ID: 17369132)
1. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
[TBL] [Abstract][Full Text] [Related]
2. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
[TBL] [Abstract][Full Text] [Related]
3. Endoglin (CD105) expression in endometrial carcinoma.
Saad RS; Jasnosz KM; Tung MY; Silverman JF
Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
[TBL] [Abstract][Full Text] [Related]
4. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Saad RS; Liu YL; Nathan G; Celebrezze J; Medich D; Silverman JF
Mod Pathol; 2004 Feb; 17(2):197-203. PubMed ID: 14657950
[TBL] [Abstract][Full Text] [Related]
5. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
6. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Raica M; Cimpean AM; Anghel A
Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
9. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
10. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
11. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
Li Q; Zhang B; Peng P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
[TBL] [Abstract][Full Text] [Related]
13. CD105 microvessels density, VEGF, EGFR-1 and c-erbB-2 and their prognostic correlation in different subtypes of cervical adenocarcinoma.
Barbu I; Crăiţoiu S; Simionescu CE; Drâgnei AM; Mărgăritescu C
Rom J Morphol Embryol; 2013; 54(3):519-30. PubMed ID: 24068399
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Yao Y; Kubota T; Takeuchi H; Sato K
Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
[TBL] [Abstract][Full Text] [Related]
15. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
16. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
17. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
18. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
[TBL] [Abstract][Full Text] [Related]
19. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
20. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
